Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5.
Benedetti DJ, Varela CR, Renfro LA, Tornwall B, Dix DB, Ehrlich PF, Glick RD, Kalapurakal J, Perlman E, Gratias E, Seibel NL, Geller JI, Khanna G, Malogolowkin M, Grundy P, Fernandez CV, Dome JS, Mullen EA. Benedetti DJ, et al. Among authors: malogolowkin m. Cancer. 2024 Mar 15;130(6):947-961. doi: 10.1002/cncr.35099. Epub 2023 Nov 7. Cancer. 2024. PMID: 37933882 Clinical Trial.
Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.
Dix DB, Seibel NL, Chi YY, Khanna G, Gratias E, Anderson JR, Mullen EA, Geller JI, Kalapurakal JA, Paulino AC, Perlman EJ, Ehrlich PF, Malogolowkin M, Gastier-Foster JM, Wagner E, Grundy PE, Fernandez CV, Dome JS. Dix DB, et al. Among authors: malogolowkin m. J Clin Oncol. 2018 Jun 1;36(16):1564-1570. doi: 10.1200/JCO.2017.77.1931. Epub 2018 Apr 16. J Clin Oncol. 2018. PMID: 29659330 Free PMC article. Clinical Trial.
Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
Dix DB, Fernandez CV, Chi YY, Mullen EA, Geller JI, Gratias EJ, Khanna G, Kalapurakal JA, Perlman EJ, Seibel NL, Ehrlich PF, Malogolowkin M, Anderson J, Gastier-Foster J, Shamberger RC, Kim Y, Grundy PE, Dome JS; AREN0532 and AREN0533 study committees. Dix DB, et al. Among authors: malogolowkin m. J Clin Oncol. 2019 Oct 20;37(30):2769-2777. doi: 10.1200/JCO.18.01972. Epub 2019 Aug 26. J Clin Oncol. 2019. PMID: 31449468 Free PMC article.
Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PR, Grundy PE, D'Angio GJ, Beckwith JB, Shamberger RC, Haase GM, Donaldson M, Weetman R, Coppes MJ, Shearer P, Coccia P, Kletzel M, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D; National Wilms Tumor Study Group. Malogolowkin M, et al. Pediatr Blood Cancer. 2008 Feb;50(2):236-41. doi: 10.1002/pbc.21267. Pediatr Blood Cancer. 2008. PMID: 17539021 Clinical Trial.
Children's Oncology Group's 2013 blueprint for research: renal tumors.
Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, Gratias EJ, Dix DB, Ehrlich PF, Khanna G, Malogolowkin MH, Anderson JR, Naranjo A, Perlman EJ; COG Renal Tumors Committee. Dome JS, et al. Pediatr Blood Cancer. 2013 Jun;60(6):994-1000. doi: 10.1002/pbc.24419. Epub 2012 Dec 19. Pediatr Blood Cancer. 2013. PMID: 23255438 Free PMC article. Review.
Outcome of patients with Stage II/favorable histology Wilms tumor with and without local tumor spill: a report from the National Wilms Tumor Study Group.
Green DM, Breslow NE, D'Angio GJ, Malogolowkin MH, Ritchey ML, Evans AE, Beckwith JB, Perlman EJ, Shamberger RC, Peterson S, Grundy PE, Dome JS, Thomas PR, Kalapurakal JA. Green DM, et al. Among authors: malogolowkin mh. Pediatr Blood Cancer. 2014 Jan;61(1):134-9. doi: 10.1002/pbc.24658. Epub 2013 Aug 23. Pediatr Blood Cancer. 2014. PMID: 24038736 Free PMC article. Clinical Trial.
Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
Mullen EA, Chi YY, Hibbitts E, Anderson JR, Steacy KJ, Geller JI, Green DM, Khanna G, Malogolowkin MH, Grundy PE, Fernandez CV, Dome JS. Mullen EA, et al. Among authors: malogolowkin mh. J Clin Oncol. 2018 Oct 18;36(34):JCO1800076. doi: 10.1200/JCO.18.00076. Online ahead of print. J Clin Oncol. 2018. PMID: 30335557 Free PMC article.
Management of Wilms' tumour: current practice and future goals.
Kalapurakal JA, Dome JS, Perlman EJ, Malogolowkin M, Haase GM, Grundy P, Coppes MJ. Kalapurakal JA, et al. Among authors: malogolowkin m. Lancet Oncol. 2004 Jan;5(1):37-46. doi: 10.1016/s1470-2045(03)01322-6. Lancet Oncol. 2004. PMID: 14700607 Review.
Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group.
Green DM, Cotton CA, Malogolowkin M, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PR, Grundy PE, D'Angio GJ, Beckwith JB, Shamberger RC, Haase GM, Donaldson M, Weetman R, Coppes MJ, Shearer P, Coccia P, Kletzel M, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D. Green DM, et al. Among authors: malogolowkin m. Pediatr Blood Cancer. 2007 May;48(5):493-9. doi: 10.1002/pbc.20822. Pediatr Blood Cancer. 2007. PMID: 16547940
116 results